PALO ALTO, Calif. — February 8, 2022 — Medable Inc., the leading software provider for patient-centered clinical trials, today launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials. The network includes new partnerships with Advanced Clinical, Cognizant and CVS, and expanded relationships with Datavant, Oracle, Parexel, PPD, part of Thermo Fisher Scientific, and Syneos Health. These partners share in Medable’s mission to get more effective therapies to patients faster.
“The next stage of clinical trial transformation is collaboration at scale. Accelerating innovation requires an ecosystem, so we’ve created the Medable Partner Network to simplify collaboration for both sponsors and partners,” said MaryAnne Rizk, Ph.D., chief strategy officer at Medable. “Our ecosystem of certified partners allows us to innovate faster together, so we can deliver smarter trials to meet the needs of patients and address the biggest challenges in healthcare.”
Today’s pharma and biotech sponsors need scalability, faster time to market, lower operating costs, and world-class technology and service partners to achieve success. Medable enables sponsors to securely build, launch, and manage studies based on a proven clinical trials platform, flexible applications, extended partner ecosystem, and 24x7 global support. The Medable Partner Network allows sponsors to scale their strategies to put patients at the center of care with remote trial access, superior user experiences, and a range of services, connected devices, and data sources.
Medable empowers partners to provide differentiated value and rapidly build revenue streams through four offerings: 1) Strategic alignment across therapeutic areas; 2) Preconfigured solutions and go-to-market delivery; 3) Technical enablement; and 4) Design innovation. Medable also provides partners with Medable Academy training and certification, enabling them to deepen their decentralized trial experience with real-world insights from a team of scientific, medical, and technical experts. Medable has now certified nearly 1,000 individuals to manage and support decentralized trials with high standards of compliance, privacy, security, and safety.
Medable Partner Network categories include:
Medable has deployed its SaaS platform via more than 150 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. By minimizing the need for in-person site visits, Medable customers have achieved impressive results – including 200 percent faster enrollment, 90 percent retention rates, and 50 percent cost reductions. A new study from Tufts Center for the Study of Drug Development shows that, on average, decentralized trials can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, due to reduced trial timelines and other factors.
For more information about the Medable Partner Network and individual partners, click here. For additional insight about decentralized trial adoption and patient-centered research, follow Medable via our blog, LinkedIn, Twitter, and Facebook channels.
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention, and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. Medable connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.
Lisa Barbadora, Big Valley Marketing for Medable, +1 (610) 420-3413, email@example.com